Acalabrutinib (Calquence) for previously untreated chronic lymphocytic leukemia - Details


( Last Updated : January 25, 2021)
Generic Name:
Acalabrutinib
Project Status:
Complete
Therapeutic Area:
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Calquence
Project Line:
Reimbursement Review
Project Number:
PC0210-000
NOC Date:

Details


Strength:
100 mg
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia (CLL) (previously untreated)
Funding Request:
With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate.
Review Status:
Complete
Sponsor:
AstraZeneca Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.